NASH/MASH Treatment Market Moves Into Its First Real Commercial Phase as Approved Therapies, GLP 1 Drugs and Fibrosis Screening Change the Treatment Pathway
The NASH/MASH treatment market is entering a new commercial era following the approval of the first liver-directed therapy and growing adoption of GLP-1-based treatments. Rising rates of obesity, type 2 diabetes, and metabolic syndrome are expanding the patient population at risk for advanced liver disease, while non-invasive fibrosis screening is improving diagnosis and treatment access. According to DataM Intelligence, the global NASH/MASH Treatment Market is expected to grow significantly through 2035, fueled by advances in pharmacotherapy, increasing awareness, and expanding treatment pathways for patients with Stage 2 to 3 fibrosis.
Jul 8, 2026
